Description
ASP1951 is an experimental drug being studied by Astellas Pharma. It is currently in Phase 1 clinical trials for various advanced solid tumors, including colorectal cancer. These early-stage trials are designed to determine the safest dose and how patients respond to the drug. ASP1951 is being tested both by itself (monotherapy) and in combination with pembrolizumab, an immunotherapy drug. The trials are looking at patients whose tumors have specific characteristics, such as ALK, EGFR, or PD-L1 mutations or expression levels. The goal of these trials is to see if ASP1951 is safe and shows signs of effectiveness in treating these cancers. It is important to remember that ASP1951 is still under investigation and is not yet approved for treating colorectal cancer or any other condition.
Mechanism of Action
ASP1951 is being studied as a potential treatment for advanced solid tumors. The specific way it works (its mechanism of action) is being investigated in clinical trials. It is being tested alone and in combination with pembrolizumab. The trials are evaluating different doses to find the optimal balance between safety and effectiveness. The drug is being studied in patients with tumors that have certain genetic markers (ALK, EGFR mutations) or protein expression levels (PD-L1).
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.